SlideShare a Scribd company logo
I-Corps 10/11/2011 Advanced Chemistry for Pharmaceutical Progress Team: Kiel Neumann (EL) Stephen DiMagno (PI) Allan Green (Mentor)
I-Corps 10/11/11 ,[object Object],[object Object],[object Object],[object Object]
General methodology for adding fluorine to lead compounds of interest The Business Model Canvas Accessibility (RCY) Purity Speed PET/SPECT Multiplatform Sensitivity (nca) Specific compounds IP PoP data Regulatory plan Understanding of the regulatory process Contract cGMP precursor manufacture Salary, Rents Clinical trials SOPs for precursors and drugs Recruit clinical sites In vivo animal studies Develop regulatory plan for pre IND meeting ID cGMP CRO Fund-raising cGMP manufacturer Radiopharmacies Nuclear Medicine and Radiology departments Technical Assistance (Image Atlas) FDA regulatory support Radiopharmacies Equipment producers Prescribing physicians Radiologist who perform studies Sales of intermediates Technology license Product license (royalty) Direct sales of precursor R&D and clinical studies presented in journals and meetings Drug developers Pharmaceutical development companies IP PoP data Radiologists Technical assistance
I-Corps 10/11/11 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],I-Corps 10/12/11
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],I-Corps 10/12/11
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
I-Corps 10/11/11 Approximately 2.2 million procedures in the US. Drug costs range from $700 (on-patent) to ~$150 (generic FDG) US sales of radiopharmaceuticals for PET and SPECT $1.2 billion US sales expected to grow to $6 billion by 2018 Global numbers approximately 2x Source: Bio-Tech Systems Report #330; data for 2010.
I-Corps 10/11/11 2500 installed PET scanners PET radiopharmacies cover the entire US market Radiopharmacies have an interest in proprietary agents as a basis of competition in their market.
I-Corps 10/11/11 Neuroblastoma Prevalence: about 6000 US cases  about 1000 new cases per year Subjects receive 3-6 images/year to follow response to therapeutic protocols World market at U.S. x 2 gives potential of 40,000-70,000 scans/year Drug costs $500/per gives ~$20 - $35 M Parkinson’s Disease DatSCAN sales in Europe ~$100 M The world's highest recorded prevalence of Parkinson's Disease of any region is in Nebraska, with 329.3 people per 100,000 population US – 600,000 patients 1 scan per year @ $500 = $300 M

More Related Content

What's hot

Survival guide to stem cell research and therapies
Survival guide to stem cell research and therapiesSurvival guide to stem cell research and therapies
Survival guide to stem cell research and therapies
Arete-Zoe, LLC
 
SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005
SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005
SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005
SterneKessler
 
Utility must be specific, practical
Utility must be specific, practicalUtility must be specific, practical
Utility must be specific, practical
Lawrence Kass
 
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global MarketsNucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
ReportsnReports
 
Genomics, Bioinformatics, and Pathology
Genomics, Bioinformatics, and PathologyGenomics, Bioinformatics, and Pathology
Genomics, Bioinformatics, and Pathology
Dan Gaston
 
PhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeq
PhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeqPhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeq
PhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeq
Golden Helix
 
Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)
Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)
Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)
Kevin Jaglinski
 

What's hot (20)

Optimizing the Output of Your Molecular Pathology Laboratory
Optimizing the Output of Your Molecular Pathology LaboratoryOptimizing the Output of Your Molecular Pathology Laboratory
Optimizing the Output of Your Molecular Pathology Laboratory
 
Ownership Rights Patents For Derivatives Of The Human Body
Ownership Rights   Patents For Derivatives Of The Human BodyOwnership Rights   Patents For Derivatives Of The Human Body
Ownership Rights Patents For Derivatives Of The Human Body
 
Organ Specific Proteomics
Organ Specific ProteomicsOrgan Specific Proteomics
Organ Specific Proteomics
 
Ownership Rights:: Patents for Derivatives of the Human Body
Ownership Rights:: Patents for Derivatives of the Human Body Ownership Rights:: Patents for Derivatives of the Human Body
Ownership Rights:: Patents for Derivatives of the Human Body
 
Survival guide to stem cell research and therapies
Survival guide to stem cell research and therapiesSurvival guide to stem cell research and therapies
Survival guide to stem cell research and therapies
 
Jax bio dataworldcongress.ngs.20181128finalwithoutbu
Jax bio dataworldcongress.ngs.20181128finalwithoutbuJax bio dataworldcongress.ngs.20181128finalwithoutbu
Jax bio dataworldcongress.ngs.20181128finalwithoutbu
 
Patentable Subject Matter” nurture or neglect innovation? A case study based ...
Patentable Subject Matter” nurture or neglect innovation? A case study based ...Patentable Subject Matter” nurture or neglect innovation? A case study based ...
Patentable Subject Matter” nurture or neglect innovation? A case study based ...
 
SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005
SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005
SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005
 
Presentation at Bio-Europe Conference, Munich. November 2010
Presentation at Bio-Europe Conference, Munich. November 2010Presentation at Bio-Europe Conference, Munich. November 2010
Presentation at Bio-Europe Conference, Munich. November 2010
 
Personalized Medicine: Genetic Diagnostics Technologies
Personalized Medicine: Genetic Diagnostics TechnologiesPersonalized Medicine: Genetic Diagnostics Technologies
Personalized Medicine: Genetic Diagnostics Technologies
 
Utility must be specific, practical
Utility must be specific, practicalUtility must be specific, practical
Utility must be specific, practical
 
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global MarketsNucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
 
Presentation at BioPartnering Europe Conference, London. October 2010
Presentation at BioPartnering Europe Conference, London. October 2010Presentation at BioPartnering Europe Conference, London. October 2010
Presentation at BioPartnering Europe Conference, London. October 2010
 
After Myriad: Where next for gene patents in the US? by Patent Attorney Dr Mi...
After Myriad: Where next for gene patents in the US? by Patent Attorney Dr Mi...After Myriad: Where next for gene patents in the US? by Patent Attorney Dr Mi...
After Myriad: Where next for gene patents in the US? by Patent Attorney Dr Mi...
 
Obtaining patentable claims after Prometheus and Myriad
Obtaining patentable claims after Prometheus and MyriadObtaining patentable claims after Prometheus and Myriad
Obtaining patentable claims after Prometheus and Myriad
 
Elemental Breath
Elemental BreathElemental Breath
Elemental Breath
 
Genomics, Bioinformatics, and Pathology
Genomics, Bioinformatics, and PathologyGenomics, Bioinformatics, and Pathology
Genomics, Bioinformatics, and Pathology
 
PhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeq
PhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeqPhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeq
PhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeq
 
2016 ngs health_lecture
2016 ngs health_lecture2016 ngs health_lecture
2016 ngs health_lecture
 
Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)
Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)
Organ-i World Transplant Congress Soild Organ Rejection Test (k-SORT)
 

Viewers also liked

Graphene frontiers lecture 3 value prop
Graphene frontiers lecture 3 value propGraphene frontiers lecture 3 value prop
Graphene frontiers lecture 3 value prop
Stanford University
 
Ground Flour Pharma Lecture 4 Channels
Ground Flour Pharma Lecture 4 ChannelsGround Flour Pharma Lecture 4 Channels
Ground Flour Pharma Lecture 4 Channels
Stanford University
 
Arka lighting lecture 3 value prop
Arka lighting lecture 3 value propArka lighting lecture 3 value prop
Arka lighting lecture 3 value prop
Stanford University
 
Carbon Cultures Lecture 4 Channels
Carbon Cultures Lecture 4 ChannelsCarbon Cultures Lecture 4 Channels
Carbon Cultures Lecture 4 Channels
Stanford University
 
Composite Nanocoatings NSF FInal Presentation
Composite Nanocoatings NSF FInal PresentationComposite Nanocoatings NSF FInal Presentation
Composite Nanocoatings NSF FInal Presentation
Stanford University
 
Carbon cultures lecture 3 value prop
Carbon cultures lecture 3 value propCarbon cultures lecture 3 value prop
Carbon cultures lecture 3 value prop
Stanford University
 
I decide fast Lecture 4 Channels
I decide fast Lecture 4 ChannelsI decide fast Lecture 4 Channels
I decide fast Lecture 4 Channels
Stanford University
 
Inserogen lecture 5 cust relationships
Inserogen lecture 5 cust relationshipsInserogen lecture 5 cust relationships
Inserogen lecture 5 cust relationships
Stanford University
 
Lecture 3 NSF I-Corps March 2012 customers
Lecture 3 NSF I-Corps March 2012 customersLecture 3 NSF I-Corps March 2012 customers
Lecture 3 NSF I-Corps March 2012 customers
Stanford University
 
Managing the flipped classroom llp educators course jan 2013
Managing the flipped classroom llp educators course jan 2013Managing the flipped classroom llp educators course jan 2013
Managing the flipped classroom llp educators course jan 2013
Stanford University
 

Viewers also liked (20)

Tex cone Lecture 4 Channels
Tex cone Lecture 4 ChannelsTex cone Lecture 4 Channels
Tex cone Lecture 4 Channels
 
E245 mammoptics wk2
E245 mammoptics wk2E245 mammoptics wk2
E245 mammoptics wk2
 
Graphene frontiers lecture 3 value prop
Graphene frontiers lecture 3 value propGraphene frontiers lecture 3 value prop
Graphene frontiers lecture 3 value prop
 
Ground Flour Pharma Lecture 4 Channels
Ground Flour Pharma Lecture 4 ChannelsGround Flour Pharma Lecture 4 Channels
Ground Flour Pharma Lecture 4 Channels
 
Arka lighting lecture 3 value prop
Arka lighting lecture 3 value propArka lighting lecture 3 value prop
Arka lighting lecture 3 value prop
 
NSF SBIR program and I-Corps
NSF SBIR program and I-CorpsNSF SBIR program and I-Corps
NSF SBIR program and I-Corps
 
Ion express Lecture 4 Channels
Ion express Lecture 4 ChannelsIon express Lecture 4 Channels
Ion express Lecture 4 Channels
 
Carbon Cultures Lecture 4 Channels
Carbon Cultures Lecture 4 ChannelsCarbon Cultures Lecture 4 Channels
Carbon Cultures Lecture 4 Channels
 
Smart menu Lecture 4 Channels
Smart menu Lecture 4 ChannelsSmart menu Lecture 4 Channels
Smart menu Lecture 4 Channels
 
Privacy Lecture 4 Channels
Privacy Lecture 4 ChannelsPrivacy Lecture 4 Channels
Privacy Lecture 4 Channels
 
Composite Nanocoatings NSF FInal Presentation
Composite Nanocoatings NSF FInal PresentationComposite Nanocoatings NSF FInal Presentation
Composite Nanocoatings NSF FInal Presentation
 
Mobidemics Lecture 4 Channels
Mobidemics Lecture 4 ChannelsMobidemics Lecture 4 Channels
Mobidemics Lecture 4 Channels
 
Arka lights Lecture 4 Channels
Arka lights Lecture 4 ChannelsArka lights Lecture 4 Channels
Arka lights Lecture 4 Channels
 
Carbon cultures lecture 3 value prop
Carbon cultures lecture 3 value propCarbon cultures lecture 3 value prop
Carbon cultures lecture 3 value prop
 
I decide fast Lecture 4 Channels
I decide fast Lecture 4 ChannelsI decide fast Lecture 4 Channels
I decide fast Lecture 4 Channels
 
Inserogen lecture 5 cust relationships
Inserogen lecture 5 cust relationshipsInserogen lecture 5 cust relationships
Inserogen lecture 5 cust relationships
 
Inserogen Lecture 4 Channels
Inserogen Lecture 4 ChannelsInserogen Lecture 4 Channels
Inserogen Lecture 4 Channels
 
Lecture 3 NSF I-Corps March 2012 customers
Lecture 3 NSF I-Corps March 2012 customersLecture 3 NSF I-Corps March 2012 customers
Lecture 3 NSF I-Corps March 2012 customers
 
Managing the flipped classroom llp educators course jan 2013
Managing the flipped classroom llp educators course jan 2013Managing the flipped classroom llp educators course jan 2013
Managing the flipped classroom llp educators course jan 2013
 
Day 1 template
Day 1 template Day 1 template
Day 1 template
 

Similar to Ground flour pharmaceuticals lecture 3 value prop

Ground flour pharmaceuticals lecture 2 bus model canvas
Ground flour pharmaceuticals lecture 2 bus model canvasGround flour pharmaceuticals lecture 2 bus model canvas
Ground flour pharmaceuticals lecture 2 bus model canvas
Stanford University
 
Global radiopharmaceuticals market insight
Global radiopharmaceuticals market insightGlobal radiopharmaceuticals market insight
Global radiopharmaceuticals market insight
KuicK Research
 
Ground flour pharma final presentation
Ground flour pharma final presentationGround flour pharma final presentation
Ground flour pharma final presentation
Stanford University
 
BioSig Technologies Corporate Presentation - May 2015
BioSig Technologies Corporate Presentation - May 2015BioSig Technologies Corporate Presentation - May 2015
BioSig Technologies Corporate Presentation - May 2015
Greg Cash
 
Personalized medicine-genetic-diagnostics-technologies
Personalized medicine-genetic-diagnostics-technologiesPersonalized medicine-genetic-diagnostics-technologies
Personalized medicine-genetic-diagnostics-technologies
cancerdrg
 
15.15 matthew vincent
15.15 matthew vincent15.15 matthew vincent
15.15 matthew vincent
John Redaelli
 
Health Information Standards - Kevin O'Carroll
Health Information Standards - Kevin O'CarrollHealth Information Standards - Kevin O'Carroll
Health Information Standards - Kevin O'Carroll
healthcareisi
 
Nanotechnology in Consumer Products: An Update on Regulatory Responses and Li...
Nanotechnology in Consumer Products: An Update on Regulatory Responses and Li...Nanotechnology in Consumer Products: An Update on Regulatory Responses and Li...
Nanotechnology in Consumer Products: An Update on Regulatory Responses and Li...
kurfirst
 
Epigen Biosciences I-Corps@NIH 121014
Epigen Biosciences I-Corps@NIH 121014Epigen Biosciences I-Corps@NIH 121014
Epigen Biosciences I-Corps@NIH 121014
Stanford University
 
NTS crowdfunder 23 2-2013
NTS crowdfunder 23 2-2013NTS crowdfunder 23 2-2013
NTS crowdfunder 23 2-2013
nanomed
 

Similar to Ground flour pharmaceuticals lecture 3 value prop (20)

Ground flour pharmaceuticals lecture 2 bus model canvas
Ground flour pharmaceuticals lecture 2 bus model canvasGround flour pharmaceuticals lecture 2 bus model canvas
Ground flour pharmaceuticals lecture 2 bus model canvas
 
Global radiopharmaceuticals market insight
Global radiopharmaceuticals market insightGlobal radiopharmaceuticals market insight
Global radiopharmaceuticals market insight
 
Ground flour pharma final presentation
Ground flour pharma final presentationGround flour pharma final presentation
Ground flour pharma final presentation
 
BioSig Technologies Corporate Presentation - May 2015
BioSig Technologies Corporate Presentation - May 2015BioSig Technologies Corporate Presentation - May 2015
BioSig Technologies Corporate Presentation - May 2015
 
Personalized medicine-genetic-diagnostics-technologies
Personalized medicine-genetic-diagnostics-technologiesPersonalized medicine-genetic-diagnostics-technologies
Personalized medicine-genetic-diagnostics-technologies
 
Rodman and Renshaw Conference Presentation, November 2006
Rodman and Renshaw Conference Presentation, November 2006Rodman and Renshaw Conference Presentation, November 2006
Rodman and Renshaw Conference Presentation, November 2006
 
PIPEs Conference Presentations, November 2006
PIPEs Conference Presentations, November 2006PIPEs Conference Presentations, November 2006
PIPEs Conference Presentations, November 2006
 
Cost on development of new drug
Cost on development of new drugCost on development of new drug
Cost on development of new drug
 
15.15 matthew vincent
15.15 matthew vincent15.15 matthew vincent
15.15 matthew vincent
 
Sequencing Genomics: The New Big Data Driver
Sequencing Genomics:The New Big Data DriverSequencing Genomics:The New Big Data Driver
Sequencing Genomics: The New Big Data Driver
 
Health Information Standards - Kevin O'Carroll
Health Information Standards - Kevin O'CarrollHealth Information Standards - Kevin O'Carroll
Health Information Standards - Kevin O'Carroll
 
BCN Biosciences I-corps@nih 121014
BCN Biosciences I-corps@nih 121014 BCN Biosciences I-corps@nih 121014
BCN Biosciences I-corps@nih 121014
 
Impact of Big Data & Artificial Intelligence in Drug Discovery & Development ...
Impact of Big Data & Artificial Intelligence in Drug Discovery & Development ...Impact of Big Data & Artificial Intelligence in Drug Discovery & Development ...
Impact of Big Data & Artificial Intelligence in Drug Discovery & Development ...
 
Portilla Nih Resources
Portilla Nih ResourcesPortilla Nih Resources
Portilla Nih Resources
 
Nanotechnology in Consumer Products: An Update on Regulatory Responses and Li...
Nanotechnology in Consumer Products: An Update on Regulatory Responses and Li...Nanotechnology in Consumer Products: An Update on Regulatory Responses and Li...
Nanotechnology in Consumer Products: An Update on Regulatory Responses and Li...
 
Epigen Biosciences I-Corps@NIH 121014
Epigen Biosciences I-Corps@NIH 121014Epigen Biosciences I-Corps@NIH 121014
Epigen Biosciences I-Corps@NIH 121014
 
Day 2 Big Data panel at the NIH BD2K All Hands 2016 meeting
Day 2 Big Data panel at the NIH BD2K All Hands 2016 meetingDay 2 Big Data panel at the NIH BD2K All Hands 2016 meeting
Day 2 Big Data panel at the NIH BD2K All Hands 2016 meeting
 
Tct presentation final
Tct presentation finalTct presentation final
Tct presentation final
 
Indications discovery and drug repurposing
Indications discovery and drug repurposingIndications discovery and drug repurposing
Indications discovery and drug repurposing
 
NTS crowdfunder 23 2-2013
NTS crowdfunder 23 2-2013NTS crowdfunder 23 2-2013
NTS crowdfunder 23 2-2013
 

More from Stanford University

More from Stanford University (20)

Team Networks - 2022 Technology, Innovation & Great Power Competition
Team Networks  - 2022 Technology, Innovation & Great Power CompetitionTeam Networks  - 2022 Technology, Innovation & Great Power Competition
Team Networks - 2022 Technology, Innovation & Great Power Competition
 
Team LiOn Batteries - 2022 Technology, Innovation & Great Power Competition
Team LiOn Batteries  - 2022 Technology, Innovation & Great Power CompetitionTeam LiOn Batteries  - 2022 Technology, Innovation & Great Power Competition
Team LiOn Batteries - 2022 Technology, Innovation & Great Power Competition
 
Team Quantum - 2022 Technology, Innovation & Great Power Competition
Team Quantum  - 2022 Technology, Innovation & Great Power CompetitionTeam Quantum  - 2022 Technology, Innovation & Great Power Competition
Team Quantum - 2022 Technology, Innovation & Great Power Competition
 
Team Disinformation - 2022 Technology, Innovation & Great Power Competition
Team Disinformation  - 2022 Technology, Innovation & Great Power CompetitionTeam Disinformation  - 2022 Technology, Innovation & Great Power Competition
Team Disinformation - 2022 Technology, Innovation & Great Power Competition
 
Team Wargames - 2022 Technology, Innovation & Great Power Competition
Team Wargames  - 2022 Technology, Innovation & Great Power CompetitionTeam Wargames  - 2022 Technology, Innovation & Great Power Competition
Team Wargames - 2022 Technology, Innovation & Great Power Competition
 
Team Acquistion - 2022 Technology, Innovation & Great Power Competition
Team Acquistion  - 2022 Technology, Innovation & Great Power Competition Team Acquistion  - 2022 Technology, Innovation & Great Power Competition
Team Acquistion - 2022 Technology, Innovation & Great Power Competition
 
Team Climate Change - 2022 Technology, Innovation & Great Power Competition
Team Climate Change - 2022 Technology, Innovation & Great Power Competition Team Climate Change - 2022 Technology, Innovation & Great Power Competition
Team Climate Change - 2022 Technology, Innovation & Great Power Competition
 
Altuna Engr245 2022 Lessons Learned
Altuna Engr245 2022 Lessons LearnedAltuna Engr245 2022 Lessons Learned
Altuna Engr245 2022 Lessons Learned
 
Invisa Engr245 2022 Lessons Learned
Invisa Engr245 2022 Lessons LearnedInvisa Engr245 2022 Lessons Learned
Invisa Engr245 2022 Lessons Learned
 
ānanda Engr245 2022 Lessons Learned
ānanda Engr245 2022 Lessons Learnedānanda Engr245 2022 Lessons Learned
ānanda Engr245 2022 Lessons Learned
 
Gordian Knot Center Roundtable w/Depty SecDef
Gordian Knot Center Roundtable w/Depty SecDef Gordian Knot Center Roundtable w/Depty SecDef
Gordian Knot Center Roundtable w/Depty SecDef
 
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
 
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
 
Team Catena - 2021 Technology, Innovation & Great Power Competition
Team Catena - 2021 Technology, Innovation & Great Power CompetitionTeam Catena - 2021 Technology, Innovation & Great Power Competition
Team Catena - 2021 Technology, Innovation & Great Power Competition
 
Team Apollo - 2021 Technology, Innovation & Great Power Competition
Team Apollo - 2021 Technology, Innovation & Great Power CompetitionTeam Apollo - 2021 Technology, Innovation & Great Power Competition
Team Apollo - 2021 Technology, Innovation & Great Power Competition
 
Team Drone - 2021 Technology, Innovation & Great Power Competition
Team Drone - 2021 Technology, Innovation & Great Power CompetitionTeam Drone - 2021 Technology, Innovation & Great Power Competition
Team Drone - 2021 Technology, Innovation & Great Power Competition
 
Team Short Circuit - 2021 Technology, Innovation & Great Power Competition
Team Short Circuit - 2021 Technology, Innovation & Great Power CompetitionTeam Short Circuit - 2021 Technology, Innovation & Great Power Competition
Team Short Circuit - 2021 Technology, Innovation & Great Power Competition
 
Team Aurora - 2021 Technology, Innovation & Great Power Competition
Team Aurora - 2021 Technology, Innovation & Great Power CompetitionTeam Aurora - 2021 Technology, Innovation & Great Power Competition
Team Aurora - 2021 Technology, Innovation & Great Power Competition
 
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...
 
Lecture 8 - Technology, Innovation and Great Power Competition - Cyber
Lecture 8 - Technology, Innovation and Great Power Competition - CyberLecture 8 - Technology, Innovation and Great Power Competition - Cyber
Lecture 8 - Technology, Innovation and Great Power Competition - Cyber
 

Recently uploaded

IATP How-to Foreign Travel May 2024.pdff
IATP How-to Foreign Travel May 2024.pdffIATP How-to Foreign Travel May 2024.pdff
IATP How-to Foreign Travel May 2024.pdff
17thcssbs2
 
The basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptxThe basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptx
heathfieldcps1
 

Recently uploaded (20)

Basic_QTL_Marker-assisted_Selection_Sourabh.ppt
Basic_QTL_Marker-assisted_Selection_Sourabh.pptBasic_QTL_Marker-assisted_Selection_Sourabh.ppt
Basic_QTL_Marker-assisted_Selection_Sourabh.ppt
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
 
50 ĐỀ LUYỆN THI IOE LỚP 9 - NĂM HỌC 2022-2023 (CÓ LINK HÌNH, FILE AUDIO VÀ ĐÁ...
50 ĐỀ LUYỆN THI IOE LỚP 9 - NĂM HỌC 2022-2023 (CÓ LINK HÌNH, FILE AUDIO VÀ ĐÁ...50 ĐỀ LUYỆN THI IOE LỚP 9 - NĂM HỌC 2022-2023 (CÓ LINK HÌNH, FILE AUDIO VÀ ĐÁ...
50 ĐỀ LUYỆN THI IOE LỚP 9 - NĂM HỌC 2022-2023 (CÓ LINK HÌNH, FILE AUDIO VÀ ĐÁ...
 
B.ed spl. HI pdusu exam paper-2023-24.pdf
B.ed spl. HI pdusu exam paper-2023-24.pdfB.ed spl. HI pdusu exam paper-2023-24.pdf
B.ed spl. HI pdusu exam paper-2023-24.pdf
 
MARUTI SUZUKI- A Successful Joint Venture in India.pptx
MARUTI SUZUKI- A Successful Joint Venture in India.pptxMARUTI SUZUKI- A Successful Joint Venture in India.pptx
MARUTI SUZUKI- A Successful Joint Venture in India.pptx
 
IATP How-to Foreign Travel May 2024.pdff
IATP How-to Foreign Travel May 2024.pdffIATP How-to Foreign Travel May 2024.pdff
IATP How-to Foreign Travel May 2024.pdff
 
Pragya Champions Chalice 2024 Prelims & Finals Q/A set, General Quiz
Pragya Champions Chalice 2024 Prelims & Finals Q/A set, General QuizPragya Champions Chalice 2024 Prelims & Finals Q/A set, General Quiz
Pragya Champions Chalice 2024 Prelims & Finals Q/A set, General Quiz
 
Gyanartha SciBizTech Quiz slideshare.pptx
Gyanartha SciBizTech Quiz slideshare.pptxGyanartha SciBizTech Quiz slideshare.pptx
Gyanartha SciBizTech Quiz slideshare.pptx
 
Open Educational Resources Primer PowerPoint
Open Educational Resources Primer PowerPointOpen Educational Resources Primer PowerPoint
Open Educational Resources Primer PowerPoint
 
Benefits and Challenges of Using Open Educational Resources
Benefits and Challenges of Using Open Educational ResourcesBenefits and Challenges of Using Open Educational Resources
Benefits and Challenges of Using Open Educational Resources
 
Students, digital devices and success - Andreas Schleicher - 27 May 2024..pptx
Students, digital devices and success - Andreas Schleicher - 27 May 2024..pptxStudents, digital devices and success - Andreas Schleicher - 27 May 2024..pptx
Students, digital devices and success - Andreas Schleicher - 27 May 2024..pptx
 
Advances in production technology of Grapes.pdf
Advances in production technology of Grapes.pdfAdvances in production technology of Grapes.pdf
Advances in production technology of Grapes.pdf
 
How to Break the cycle of negative Thoughts
How to Break the cycle of negative ThoughtsHow to Break the cycle of negative Thoughts
How to Break the cycle of negative Thoughts
 
The impact of social media on mental health and well-being has been a topic o...
The impact of social media on mental health and well-being has been a topic o...The impact of social media on mental health and well-being has been a topic o...
The impact of social media on mental health and well-being has been a topic o...
 
The basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptxThe basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptx
 
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXXPhrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
 
2024_Student Session 2_ Set Plan Preparation.pptx
2024_Student Session 2_ Set Plan Preparation.pptx2024_Student Session 2_ Set Plan Preparation.pptx
2024_Student Session 2_ Set Plan Preparation.pptx
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
 
Introduction to Quality Improvement Essentials
Introduction to Quality Improvement EssentialsIntroduction to Quality Improvement Essentials
Introduction to Quality Improvement Essentials
 
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
 

Ground flour pharmaceuticals lecture 3 value prop

  • 1. I-Corps 10/11/2011 Advanced Chemistry for Pharmaceutical Progress Team: Kiel Neumann (EL) Stephen DiMagno (PI) Allan Green (Mentor)
  • 2.
  • 3. General methodology for adding fluorine to lead compounds of interest The Business Model Canvas Accessibility (RCY) Purity Speed PET/SPECT Multiplatform Sensitivity (nca) Specific compounds IP PoP data Regulatory plan Understanding of the regulatory process Contract cGMP precursor manufacture Salary, Rents Clinical trials SOPs for precursors and drugs Recruit clinical sites In vivo animal studies Develop regulatory plan for pre IND meeting ID cGMP CRO Fund-raising cGMP manufacturer Radiopharmacies Nuclear Medicine and Radiology departments Technical Assistance (Image Atlas) FDA regulatory support Radiopharmacies Equipment producers Prescribing physicians Radiologist who perform studies Sales of intermediates Technology license Product license (royalty) Direct sales of precursor R&D and clinical studies presented in journals and meetings Drug developers Pharmaceutical development companies IP PoP data Radiologists Technical assistance
  • 4.
  • 5.
  • 6.
  • 7.
  • 8. I-Corps 10/11/11 Approximately 2.2 million procedures in the US. Drug costs range from $700 (on-patent) to ~$150 (generic FDG) US sales of radiopharmaceuticals for PET and SPECT $1.2 billion US sales expected to grow to $6 billion by 2018 Global numbers approximately 2x Source: Bio-Tech Systems Report #330; data for 2010.
  • 9. I-Corps 10/11/11 2500 installed PET scanners PET radiopharmacies cover the entire US market Radiopharmacies have an interest in proprietary agents as a basis of competition in their market.
  • 10. I-Corps 10/11/11 Neuroblastoma Prevalence: about 6000 US cases about 1000 new cases per year Subjects receive 3-6 images/year to follow response to therapeutic protocols World market at U.S. x 2 gives potential of 40,000-70,000 scans/year Drug costs $500/per gives ~$20 - $35 M Parkinson’s Disease DatSCAN sales in Europe ~$100 M The world's highest recorded prevalence of Parkinson's Disease of any region is in Nebraska, with 329.3 people per 100,000 population US – 600,000 patients 1 scan per year @ $500 = $300 M